Antiviral Drug News and Research RSS Feed - Antiviral Drug News and Research

Antiviral-based therapies have potential to protect humans from deadly Ebola virus

Antiviral-based therapies have potential to protect humans from deadly Ebola virus

For the first time, UK physicians have demonstrated that antiviral-based therapies have the potential to protect humans from the deadly Ebola virus. The report, published in The Lancet Infectious Diseases journal, describes a case-series of eight British health-care workers who were evacuated to the Royal Free Hospital in London, UK after possible accidental exposure to Ebola virus in Sierra Leone between January and March 2015. [More]
Discovery allows study of naturally occurring forms of HCV in the lab

Discovery allows study of naturally occurring forms of HCV in the lab

Worldwide, 185 million people have chronic hepatitis C. Since the late 1980s, when scientists discovered the virus that causes the infection, they have struggled to find ways to grow it in human cells in the lab -- an essential part of learning how the virus works and developing new effective treatments. [More]
Researchers develop new genomic data set on Lassa virus

Researchers develop new genomic data set on Lassa virus

An international team of researchers has developed the largest genomic data set in the world on Lassa virus (LASV). [More]
First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

First patient enrolled in Contravir‘s FV-100 Phase 3 study to prevent shingles, shingles-associated pain

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the first patient has been enrolled in the Company's pivotal Phase 3 clinical study, study 007, of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN). [More]
Ledipasvir/sofosbuvir combination approved for hepatitis C treatment does not require antiviral drug

Ledipasvir/sofosbuvir combination approved for hepatitis C treatment does not require antiviral drug

The drug approved to treat patients infected with the hepatitis C virus needs no help from other antivirals, according to a study released online this week in the journal Hepatology. [More]
Baruch S. Blumberg Institute engaged to conduct study using ContraVir's new HBV therapeutic candidate

Baruch S. Blumberg Institute engaged to conduct study using ContraVir's new HBV therapeutic candidate

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has engaged the Baruch S. Blumberg Institute, the non-profit research sister organization of the Hepatitis B Foundation, to conduct a series of experiments using ContraVir's hepatitis B program, CMX157. [More]
Research finding could explain why HIV envelope protein has a long tail

Research finding could explain why HIV envelope protein has a long tail

Virologists at Emory University School of Medicine, Yerkes National Primate Research Center, and Children's Healthcare of Atlanta have uncovered a critical detail explaining how HIV assembles its infectious yet stealthy clothing. [More]
Telbivudine drug prevents perinatal transmission of HBV

Telbivudine drug prevents perinatal transmission of HBV

The antiviral drug telbivudine prevents perinatal transmission of hepatitis B virus (HBV), according to a study in the June issue of Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. [More]
Researchers show potential of stem cell-based therapy in treating brain-metastatic breast cancer

Researchers show potential of stem cell-based therapy in treating brain-metastatic breast cancer

Investigators from Massachusetts General Hospital and the Harvard Stem Cell Institute have developed an imageable mouse model of brain-metastatic breast cancer and shown the potential of a stem-cell-based therapy to eliminate metastatic cells from the brain and prolong survival. [More]
Personalized gene therapy to fight against cancer

Personalized gene therapy to fight against cancer

The fight to treat cancer and eradicate tumors will likely benefit from a new set of treatments if early development phases continue to show promise, according to Kalorama Information. The healthcare market research publisher stated that gene therapies that are able to deliver genetic material to a specific cell population or tumor that will result in the destruction of the tumor. [More]
Clinical study launched to evaluate effectiveness of new HCV therapy in Washington, D.C.

Clinical study launched to evaluate effectiveness of new HCV therapy in Washington, D.C.

Officials from the National Institutes of Health and the city of Washington, D.C., launched a clinical trial to examine whether primary care physicians and other health care providers, such as nurse practitioners and physician assistants, can use a new antiviral therapy as effectively as specialist physicians to treat people with hepatitis C virus (HCV) infection. [More]
Research shows effectiveness of Tamiflu

Research shows effectiveness of Tamiflu

Earlier this month, the Centers for Disease Control and Prevention recommended the use of antiviral drugs to help treat influenza, in a year when the available vaccine is not a good match for the current strain. [More]
MedExpress physicians offer appropriate option to assess, treat flu or cold symptoms

MedExpress physicians offer appropriate option to assess, treat flu or cold symptoms

As flu season progresses, patients across the country continue to seek care for flu and illness symptoms at a variety of health care locations. From doctors' offices to emergency rooms, many patients find it difficult to determine the best option based on their symptoms. MedExpress physicians remind patients, that in many cases, urgent care centers offer a convenient, appropriate option for the assessment and treatment of non-severe flu or cold symptoms. [More]
Early estimates indicate flu vaccine is providing little protection in US

Early estimates indicate flu vaccine is providing little protection in US

Each year the Centers for Disease Control and Prevention (CDC) undertake flu vaccine effectiveness studies. Early estimates for the current season indicate that those people (all ages) who had the flu vaccine were only 23% less likely to have to go to the doctor because of flu (influenza). [More]
NIAID awards contracts to support early-stage human clinical trials of infectious disease treatments

NIAID awards contracts to support early-stage human clinical trials of infectious disease treatments

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded contracts to three organizations to support early-stage human clinical trials of investigational infectious disease treatments. The new awards for the Phase I Clinical Trial Units for Therapeutics increases the number of funded organizations under the program from two to three, expanding capacity for conducting early safety testing of novel investigational drugs. [More]
ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial

ContraVir granted Type B meeting with FDA to discuss proposal for FV-100 Phase 3 trial

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has been granted a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss its proposal for the design of a Phase 3 trial of ContraVir's lead antiviral candidate, FV-100. [More]
Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, ContraVir collaborate to develop and commercialize antiviral drug candidate CMX157

Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, and ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the companies have entered into a strategic collaboration for the further clinical development and commercialization of CMX157. [More]
Monash University, 60P Australia partner to develop Fenretinide drug for dengue fever

Monash University, 60P Australia partner to develop Fenretinide drug for dengue fever

Monash University and 60P Australia Pty Ltd, a subsidiary of 60° Pharmaceuticals LLC, have announced today an exclusive partnering deal, with 60P obtaining rights to develop the drug Fenretinide for dengue fever. [More]
UTMB researchers receive awards at American Society of Tropical Medicine and Hygiene meeting

UTMB researchers receive awards at American Society of Tropical Medicine and Hygiene meeting

Scientists at the University of Texas Medical Branch were recognized with prestigious awards for their contributions in research at the annual American Society of Tropical Medicine and Hygiene meeting. [More]
Experimental Ebola treatments to be trialled in West Africa next month

Experimental Ebola treatments to be trialled in West Africa next month

Médecins Sans Frontières/Doctors without Borders (MSF) have announced that three trials of Ebola therapies will begin in West Africa this December. [More]
Advertisement
Advertisement